ClinicaliQ Trial Snapshot
- A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer — Recruiting • Phase III • Oncology •….
- What is being tested: Divarasib (a KRAS G12C inhibitor) combined with pembrolizumab (immunotherapy) versus standard chemotherapy (pemetrexed plus carboplatin or cisplatin) combined with pembrolizumab as first-line treatment for KRAS G12C-mutated advanced/metastatic non-squamous non-small cell lung cancer.
- Patient eligibility overview: Adults with previously untreated, advanced or metastatic non-squamous non-small cell lung cancer confirmed to have KRAS G12C mutations are eligible for this trial.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).
Eligibility Snapshot
- : * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Histologically or cytologically confirmed diagnosis of advanced or metastatic non squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy * Measurable disease, as defined by RECIST v1.1 * No prior systemic treatment for advanced or metastatic NSCLC * Documentation of the presence of a KRAS G12C mutation * Documentation of known PD-L1 expression status in tumor tissue * Availability of a representative tumor specimen * Adequate end-organ function * Eligible to receive a platinum-based chemotherapy regimen
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.